Bacterial control through dispersion of bacteriophage powders.
20230363396 · 2023-11-16
Inventors
Cpc classification
A61L2/23
HUMAN NECESSITIES
A01P1/00
HUMAN NECESSITIES
International classification
A01P1/00
HUMAN NECESSITIES
Abstract
A method of eliminating, reducing or preventing bacterial contamination of a surface, the method comprising dispersing a bacteriophage containing composition in air in proximity to the surface. In some embodiments, the bacteriophage containing composition is a powder dispersed by pressurizing a load chamber containing the powder so that the powder is expelled through an outlet. Also, devices for performing the method and a powder used in the method.
Claims
1. A method using bacteriophages for at least partially disinfecting a surface exposed to air, the method comprising: providing a powder, the powder including bacteriophages; and dispersing the powder in the air in proximity of the surface to apply at least part of the powder on the surface, wherein the powder is dispersed nonpyrogenically using a dry dispersion mechanism.
2. The method as defined in claim 1, wherein providing the powder includes providing the powder in a load chamber; and dispersing the powder includes pressurizing the load chamber to a dispersion pressure larger than atmospheric pressure to expel the powder out of the load chamber.
3. The method as defined in claim 2, wherein pressurizing the load chamber includes introducing a pressurized gas having a gas pressure larger than atmospheric pressure in the load chamber.
4. The method as defined in claim 2, wherein the load chamber is at least in part destroyed when the pressurized gas is introduced in the load chamber.
5. The method as defined in claim 2, wherein the powder is expelled out of the load chamber through at least one nozzle in fluid communication with the load chamber.
6. The method as defined in claim 1, wherein the powder consists essentially of bacteriophages.
7. The method as defined in claim 6, wherein the bacteriophages are in the form of lyophilized bacteriophage particles.
8. The method as defined in claim 1, wherein the powder further includes auxiliary particles.
9. The method as defined in claim 8, wherein the powder includes lyophilized bacteriophage particles dispersed in the auxiliary particles.
10. The method as defined in claim 9, wherein, the lyophilized bacteriophage particles make up from about 1 percent to about 50 percent in mass of the powder.
11. The method as defined in claim 8, wherein the auxiliary particles are selected from the group consisting of inorganic salt particles, hydrophobic polymer particles, silica particles, polyvinylpyrrolidone particles, cellulose ethers particles, polyethylene glycol particles, polyvinyl alcohol particles, poloxamers particles MgSO.sub.4 particles, MgCO.sub.3 particles, CaCO.sub.3 particles and talc particles, ionic surfactant particles, non-ionic surfactant particles, magnesium aluminometasilicate particles, cyclodextrins particles, magnesium stearate particles, starch particles, bactericide particles, detergents particles, antibiotics particles, nanoparticles, metallic powders particles, Ag particles, Cu particles, AgCu alloys particles, bimetallic nanoparticles, FeO.sub.4 particles, FeO.sub.3 particles, FeO particles superparamagnetic particles, and combinations thereof.
12. The method as defined in claim 8, wherein at least part of the bacteriophages are immobilized on the auxiliary particles.
13. The method as defined in claim 7, wherein at least 95 percent of the lyophilized bacteriophage particles in particle number has less than about 180 μm in size.
14. The method as defined in claim 7, wherein at least 95 percent in mass of the lyophilized bacteriophage particles has less than about 180 μm in size.
15. The method as defined in claim 7, wherein at least 95 percent of the lyophilized bacteriophage particles in particle number has less than about 45 μm in size.
16. The method as defined in claim 7, wherein at least 95 percent in mass of the lyophilized bacteriophage particles has less than about 45 μm in size.
17. The method as defined in claim 13, wherein at least 95 percent of the lyophilized bacteriophage particles in number have more than about 10 μm in size.
18. The method as defined in claim 14, wherein at least 95 percent of the lyophilized bacteriophage particles in mass has more than about 10 μm in size.
19. The method as defined in claim 1, wherein the load chamber is pressurized to between about 4 MPa and about 7 MPa.
20. The method as defined in claim 1, wherein dispersing the powder includes aerosolizing the powder.
21. The method as defined in claim 1, wherein the surface include one of a room surface inside a room, a vehicle surface inside a vehicle, an exposed wound surface, a conduit surface inside a conduit, an outdoors surface in the environment or combinations thereof.
22. The method as defined in claim 1, further comprising lysing bacteria present on the surface with the bacteriophages.
23. A device for at least partially disinfecting a surface exposed to air using bacteriophages, the device comprising: a pressurized gas source for providing a pressurized gas at a pressure larger than atmospheric pressure; a load chamber containing a powder, the powder including the bacteriophages; a valve provided between the pressurized gas source and the load chamber, the valve being configurable between a closed configuration in which the pressurized gas is prevented from entering the load chamber and an open configuration in which the pressurized gas is allowed to enter the load chamber to pressurize the latter; and an actuator for selectively moving the valve from the closed to the open configuration; wherein, when the valve is configured from the closed configuration to the open configuration, the pressurized gas enters the chamber and expels the powder therefrom and into the air through an outlet.
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)
38. (canceled)
39. (canceled)
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. (canceled)
46. (canceled)
47. (canceled)
48. (canceled)
49. (canceled)
50. A powder comprising: lyophilized bacteriophage particles; and biologically inactive auxiliary particles; wherein the powder includes between 1% and 50% in mass of the lyophilized bacteriophage particles.
51. (canceled)
52. (canceled)
53. (canceled)
54. (canceled)
55. (canceled)
56. (canceled)
57. (canceled)
58. (canceled)
59. (canceled)
60. (canceled)
61. (canceled)
62. (canceled)
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0054] In the drawings:
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
DETAILED DESCRIPTION
[0066] It is proposed to treat a surface exposed to air to at least partially disinfect the surface, for example by eliminating, reducing or preventing bacterial contamination of the surface using a powder, the powder including bacteriophages. The powder including bacteriophages is referred to herein as “the powder”. The bacteriophages may be in the form of lyophilized bacteriophage fine particles, either purely such particles or in the presence of auxiliary particles, or include bacteriophages that are immobilized on fine particles. The fine particles, also referred to simply as “particles” have a dimension small enough to remain suspended in air for a duration long enough that when suspended, the particles can diffuse or move through convection adjacent the surface to treat to eventually contact the surface.
[0067] In some embodiments, the powder includes lyophilized bacteriophage particles, or consists essentially of such lyophilized bacteriophage particles, and at least 95 percent in mass or in particle numbers of the lyophilized bacteriophage particles have less than about 180 μm in size or less than about 45 μm in size. In some embodiments, at least 95 percent in mass or in particle numbers of the of the lyophilized bacteriophage particles includes particles having more than about 10 μm in size. If other particles are present in the powder, such as auxiliary particles detailed hereinbelow, the size distribution for the other particles can meet the same limits as the ones mentioned for the lyophilized bacteriophage particles, or the size distribution for the other particles can differ from these limits. For example, having the other particles that are larger than the lyophilized bacteriophage particles may be acceptable or even desirable in some embodiments. For example, larger particles may settle faster and travel less than the bacteriophage particles, but help in the initial dispersion or during manufacturing of the powder.
[0068] In some embodiments, the surface to treat is in a room or any other enclosed or mostly enclosed space and most or all of the surfaces present in the room may be treated. Example of such spaces include hospital patient rooms, operating rooms, intensive care units, and other medical treatment facilities. Temporary structures, such as tents, and vehicles, such as ambulances and military vehicles, could also benefit from the proposed treatment method. In other embodiments, the surface to treat is the internal surface of a water or air conduit. In yet other embodiments, the surface to treat is an exposed surface of a wound. In other embodiments, the particles are dispersed outside, in the environment, for example to decontaminate agricultural fields or outdoor surfaces contaminated by biological weapons. The proposed method may also be used to provide respiratory therapy to a patient, a human or a non-human mammal, suffering from a bacterial infection, by dispersing the powder as above and having the patient inhale the powder suspended or aerosolized in the air. In such cases, bacteriophages intended to treat the pulmonary infection are provided.
[0069] When auxiliary particles are present, they may include one or more of inorganic salt particles, hydrophobic polymer particles, such as the polymers described in US patent application publication US20160375139A1 published Dec. 29, 2016, the contents of which is hereby incorporated by reference in its entirety, silica, polyvinylpyrrolidone, cellulose ethers, polyethylene glycol, polyvinyl alcohol or poloxamers. Other examples of auxiliary particles include particles of inorganic salts, such as MgSO.sub.4, MgCO.sub.3, CaCO.sub.3 and talc. Yet other example of suitable auxiliary particles include surfactants, ionic or non-ionic. Yet other example of suitable auxiliary particles include magnesium aluminometasilicate, cyclodextrins, talc, magnesium stearate, and starch, and bactericide particles, such as detergents, antibiotics or other bactericides, such as nanoparticles, metallic powders, for example AG, Cu, AGCU alloys, bimetallic nanoparticles, could also be contained in the composition, if compatible with bacteriophage viability. In yet other embodiments, the auxiliary particles include FeO.sub.4, FeO.sub.3, FeO, superparamagnetic particles, and combinations thereof. In some embodiments, the bacteriophages are adsorbed on the surface of solid particles, lyophilized, spray-dried or dispersed in degradable particles that will experience relatively quick degradation upon contact with the atmosphere or the surface. In some embodiments, the composition replaces the bacteriophages with phage-related products, or includes such phage-related products in addition to the bacteriophages. Examples of such phage-related products include endolysins, phage proteins, phage enzymatic formulations, and combinations thereof.
[0070] The particles may be discharged in air in any suitable manner. An advantageous way of performing this discharge is to use a sudden increase in pressure in a container using a compressed gas. In some embodiments, the container is destroyed when the pressure increase is created. In other embodiments, the container includes an exhaust having a shape suitable to allow dispersion of the particles through the exhaust when the pressure is increased in the container. The exhaust may be used to control or influence the direction in which the particles are spread and the speed at which they are ejected.
[0071] Referring to
[0072] The pressurized gas source 12 is of any type that may provide enough gas at enough pressure to cause dispersion of the powder in the air. For example, referring to
[0073] In some embodiments, the compressed gas cartridge 36 is replaced after each use or after a predetermined number of uses of the device 10. The compressed gas cartridge 36 is therefore provided filled with a compressed gas and discarded or sent for refilling when the pressure in the compressed gas cartridge 36 is too low.
[0074] In other embodiments (not shown in the drawings), the pressurized gas source 12 includes a chamber that can be pressurized using a compressed gas, for example through a commercial compressed gas cylinder. Other manners of providing the compressed gas are also within the scope of the appended claims.
[0075] As seen in
[0076] Referring to
[0077] In yet other embodiments, the controller 28 is operative for periodically dispersing a predetermined quantity of the powder 15 at predetermined time intervals. For example, the controller 28 includes a microcontroller running software operative for periodically opening the valve 18 for a predetermined duration and immediately after closing the valve 18. These periodic dispersals of the powder 15 may for example be performed many times before there is a need to reload the load chamber 14, or the device 10 may then be provided with a powder dispenser that refills the load chamber 14 after each powder 15 dispersal. For example the powder dispenser includes a container containing the powder 15 and is provided with an access door leading into the load chamber 14, so that the access door may be opened to reload the load chamber 14 each time the device 10 has dispersed the powder 15. Other suitable mechanisms for refilling the load chamber 14 automatically may also be used. Periodic dispersal may be performed in “burst” mode, wherein pressurization of the load chamber 14 is performed at intervals of a few seconds to a few minutes from each other, or over a more extended time period, wherein the pressurization of the load chamber 14 is performed at intervals of more than a few minutes to weekly or monthly intervals.
[0078] An example of a purely mechanical controller is shown for device 100 of
[0079] The load chambers 14 and 114 contain the powder 15 to be dispersed.
[0080] Reference will be made below to the load chamber 14 for simplicity, but the load chamber 114 operates similarly to the load chamber 14. These powders 15 could be provided directly into a load chamber 14 strong enough to withstand the relatively large pressures required for dispersion of the powder 15. In such cases, a diaphragm 33 or 132, seen in
[0081] In other embodiments, the diaphragm 132 is part of a capsule including the powder 15. Indeed, to facilitate handling of the fine particle loads, the powder 15 may come packaged in a capsule including an outer shell, made of a material similar to that from which the diaphragm 132 may be made, containing the powder 15. For example, the outer shell may be fragile enough to allow relatively easy penetration of the poppet valve head 117 thereinto when the valve is opened, which leads to sudden pressurization of the outer shell and release of the fine particles as the diaphragm 132 is damaged or destroyed.
[0082] The powder 15 may substantially entirely fill the load chamber 14, either relatively loosely or compressed. Alternatively, only a fraction of the load chamber 14 may be filled with the powder 15.
[0083] Returning to
[0084] In other embodiments, the load chamber 14 is filled with a liquid including bacteriophages, or with a liquid suspension of particles with bacteriophages adsorbed or dispersed in the particles and/or dispersed in the liquid. In some embodiments, the quantity of bacteriophages contained in each load of the load chamber 14 is sufficient to provide between about 10.sup.4 and 10.sup.8 PFU/m.sup.2 on the surfaces to treat, but higher and lower quantities of bacteriophages are also within the scope of the invention.
[0085] In yet other embodiments, a device similar to the devices 10 and 100 is single-use. In yet other embodiments, a device 200, seen in
[0086] For example the valve 218 is simply a pin or other similar structure that obstructs an aperture extending between the load chamber 214 and compressed gas chamber 212 and which, when slid perpendicularly to the aperture, releases the gas. Other suitable valves 218 are usable.
[0087] The above-described devices 10, 100 and 200, along with any alternative suitable devices, may be used to perform a method 300 using bacteriophages for at least partially disinfecting a surface exposed to air and illustrated in
[0088] Once in the air, part of the powder 15 may settle on the surface to treat. It should be noted that due to the small size of the particles, this surface may be at a relatively large distance from the powder release site, such as many meters or even more from the powder release site.
[0089] In some embodiments, the powder 15 may only include a small fraction of its mass in bacteriophages particles, for example between 1% and 50%, the remainder being in the form of auxiliary particles, and nevertheless remain effective. This is detailed in example 1.
Example 1
[0090] An SPK bacteriophage cocktail (active against Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumoniae bacteria, 1.4×10.sup.9 PFU/ml) was diluted 1/10 in Trehalose 0.5M and lyophilized using the following cycle and stored at 4° C.
TABLE-US-00001 Temperature Rate Time (° C.) (° C./min) (h) Comments −40 0.67 1.3 Put samples in −40 0 3 Vacuum on 0 1 18 25 0.07 6 4 1 Indef Cap and Remove
[0091] As a control of phage activity, 1 vial of lyophilized SPK cocktail (mean weight of 100 mg) was resuspended in 1 mL of sterile water and tittered SMQ-121 (SaX), ATCC15442 (PsA-159) and KP27 for S. aureus, P. aeruginosa and K. pneumoniae phages, respectively. The table below presents phage titer per mL and g of lyophilized phage powder.
TABLE-US-00002 Bacteria Titer (PFU/mL) Titer (PFU/g) S. aureus 2.4E05 2.4E06 P. aeruginosa 2.3E06 2.3E07 K. pneumoniae 2.1E06 2.1E07 Complete cocktail 4.64E6 4.64E7
[0092] Lyophilized phage pellets were delicately broken with a sterile spatula and homogenized with high homogenizer to make a uniform fine powder, which had a final density of 0.33 g/cm.sup.3.
[0093] Four additives (auxiliary particles) were used: Magnesium Sulfate (density 2.66 g/cm.sup.3), Magnesium Carbonate (density 2.96 g/cm.sup.3), Calcium Carbonate (density 2.71 g/cm.sup.3) and TALC: (density 0.67 g/cm.sup.3). Three dilutions of bacteriophages in additives were tested: 1:1, 1:10 and 1:100 of lyophilized phage powder in tested additives (w/w).
[0094] After mixing, activity testing was performed on 10 mg of lyophilized phage+additive mixture by pouring the powder on a layer of bacteria (1004 of bacterial culture at exponential phase in 2.5 mL of top agar). The bacteria used were SMQ-121 (SaX), ATCC15442 (PsA-159) and KP27 for S. aureus, P. aeruginosa and K. pneumoniae phages, respectively. Plates were incubated overnight at 37° C. before taking pictures with a gel doc system. In addition, negative controls of 10 mg of each additive and positive controls: of 10 mg of lyophilized SPK cocktail were used.
[0095]
[0096] Although the present invention has been described hereinabove by way of exemplary embodiments thereof, it will be readily appreciated that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, the scope of the claims should not be limited by the exemplary embodiments, but should be given the broadest interpretation consistent with the description as a whole. The present invention can thus be modified without departing from the spirit and nature of the subject invention as defined in the appended claims.